To overcome these challenges, the novel proteolysis‐targeting chimera (PROTAC) strategy has been developed, which offers greater selectivity and can induce efficient degradation with minimal quantities.[24, 25] Notably, ARV‐825, a BRD4 PROTAC, has been shown to significantly inhibit glioma growth at nanomolar concentrations by inducing apoptosis and inhibiting cell proliferation, thereby further corroborating this notion.[26] Consequently, we endeavored to incorporate ARV‐825 as an adjuvant in TMZ‐based glioma chemotherapy. This evidence concerns the gene BRD4 and glioma.